Trial watch: chemotherapy-induced immunogenic cell death in oncology.

"Disclosure statement No potential conflict of interest was reported by the authors."

"This study was supported by Research Foundation Flanders (FWO) (Fundamental Research Grant, G0B4620N to ADG; Excellence of Science/EOS grant, 30837538, for ‘DECODE’ consortium, for ADG), KU Leuven (C1 grant, C14/19/098; C3 grant, C3/21/037; and POR award funds, POR/16/040 to ADG), Kom op Tegen Kanker (KOTK/2018/11509/1 to ADG; and KOTK/2019/11955/1 to ADG), and VLIR-UOS (iBOF grant, iBOF/21/048, for ‘MIMICRY’ consortium to ADG). I.V. was supported by FWO-SB PhD Fellowship (1S06821N). J.S. was funded by Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society via Emmanuel van der Schueren (EvDS) PhD fellowship (projectID: 12699). D.M.B. was supported by KU Leuven’s Postdoctoral FWO fellowship (1279223N). R.S. was supported by FWO-SB PhD Fellowship (1S44123N); E.S. was supported by the KOTK (KOTK/2019/7878); O.K. was supported by Institut National du Cancer (INCa) and the DIM ELICIT; D.V.K. was supported by FWO-Flanders (G016221N) and Excellence of Science/EOS grant, 40007488. Research in the Vandenabeele unit was supported by the FWO (research grants G.0C76.18N, G.0B71.18N, G.0B96.20N, G.0A93.22N, EOS MODEL-IDI Grant (30826052), and EOS CD-INFLADIS (40007512)), grants from the Special Research Fund UGent (Methusalem grant BOF16/MET_V/007, iBOF ATLANTIS grant 20/IBF/039), grants from the Foundation against Cancer (F/2016/865, F/2020/1505), CRIG and GIGG consortia, and VIB."